FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897175949> ?p ?o ?g. }

• W2897175949 endingPage "e12527" @default.
• W2897175949 startingPage "e12527" @default.
• W2897175949 abstract "Objectives MiR-34 is a tumour suppressor in breast cancer. Neurokinin-1 receptor (NK1R), which is the predicted target of the miR-34 family, is overexpressed in many cancers. This study investigated the correlation and clinical significance of miR-34 and NK1R in breast cancer. Materials and methods Western blotting, quantitative reverse transcription-PCR (qRT-PCR) and luciferase assays were conducted to analyse the regulation of NK1R by miR-34 in MDA-MB-231, MCF-7, T47D, SK-BR-3 and HEK-293 T cells. MiR-34b/c-5p, full-length NK1R (NK1R-FL) and truncated NK1R (NK1R-Tr) expression in fifty patients were quantified by qRT-PCR and correlated with their clinicopathological parameters. CCK-8 assays, colony formation assays and flow cytometry were used to measure cell proliferation and apoptosis in MDA-MB-231 and MCF-7 cells transfected with miR-34b/c-5p or NK1R-siRNA and before treatment with or without Substance P (SP), an endogenous peptide agonists of NK1R. The effect of NK1R antagonist aprepitant was also investigated. In vivo xenograft models were used to further verify the regulation of NK1R by miR-34b/c-5p. Results Expression levels of miR-34b/c-5p and NK1R-Tr, but not NK1R-FL, were associated with enhanced malignant potential, such as tumour stage and Ki67 expression. The overexpression of miR-34b/c-5p or NK1R silencing potently suppressed cell proliferation and induced G2/M phase arrest and the apoptosis of MDA-MB-231 and MCF-7 cells. The NK1R antagonist aprepitant had similar effects. In vivo studies confirmed that miR-34b/c-5p overexpression or NK1R silencing reduced the tumorigenicity of breast cancer. In addition, SP rescued the effects of miR-34b/c-5p overexpression or NK1R silencing on cell proliferation and apoptosis in vitro and in vivo assays. Conclusions MiR-34b/c-5p and NK1R contribute to breast cancer cell proliferation and apoptosis and are potential targets for breast cancer therapeutics." @default.
• W2897175949 created "2018-10-26" @default.
• W2897175949 creator A5000111816 @default.
• W2897175949 creator A5000548162 @default.
• W2897175949 creator A5008664030 @default.
• W2897175949 creator A5013345797 @default.
• W2897175949 creator A5041250002 @default.
• W2897175949 creator A5043110913 @default.
• W2897175949 creator A5058533540 @default.
• W2897175949 creator A5064802725 @default.
• W2897175949 creator A5078315542 @default.
• W2897175949 date "2018-10-17" @default.
• W2897175949 modified "2023-10-12" @default.
• W2897175949 title "MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis" @default.
• W2897175949 cites W1488537054 @default.
• W2897175949 cites W1561288175 @default.
• W2897175949 cites W1829102683 @default.
• W2897175949 cites W1889964234 @default.
• W2897175949 cites W1974658661 @default.
• W2897175949 cites W1989985271 @default.
• W2897175949 cites W1993665971 @default.
• W2897175949 cites W1995089537 @default.
• W2897175949 cites W2022322735 @default.
• W2897175949 cites W2025124981 @default.
• W2897175949 cites W2025351114 @default.
• W2897175949 cites W2025890993 @default.
• W2897175949 cites W2038809664 @default.
• W2897175949 cites W2050833196 @default.
• W2897175949 cites W2051936739 @default.
• W2897175949 cites W2052152709 @default.
• W2897175949 cites W2059117644 @default.
• W2897175949 cites W2063878022 @default.
• W2897175949 cites W2070765029 @default.
• W2897175949 cites W2076454911 @default.
• W2897175949 cites W2077399441 @default.
• W2897175949 cites W2080426042 @default.
• W2897175949 cites W2081945526 @default.
• W2897175949 cites W2103423847 @default.
• W2897175949 cites W2104268053 @default.
• W2897175949 cites W2108976777 @default.
• W2897175949 cites W2131783891 @default.
• W2897175949 cites W2132256680 @default.
• W2897175949 cites W2134302423 @default.
• W2897175949 cites W2136327958 @default.
• W2897175949 cites W2143438357 @default.
• W2897175949 cites W2147418367 @default.
• W2897175949 cites W2155487079 @default.
• W2897175949 cites W2165460739 @default.
• W2897175949 cites W2166639141 @default.
• W2897175949 cites W2166898859 @default.
• W2897175949 cites W2170779011 @default.
• W2897175949 cites W2503276177 @default.
• W2897175949 cites W2517771033 @default.
• W2897175949 cites W2570618306 @default.
• W2897175949 cites W2598710356 @default.
• W2897175949 cites W2603942390 @default.
• W2897175949 cites W2702028962 @default.
• W2897175949 cites W2766152189 @default.
• W2897175949 cites W2024275987 @default.
• W2897175949 doi "https://doi.org/10.1111/cpr.12527" @default.
• W2897175949 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6430481" @default.
• W2897175949 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30334298" @default.
• W2897175949 hasPublicationYear "2018" @default.
• W2897175949 type Work @default.
• W2897175949 sameAs 2897175949 @default.
• W2897175949 citedByCount "36" @default.
• W2897175949 countsByYear W28971759492019 @default.
• W2897175949 countsByYear W28971759492020 @default.
• W2897175949 countsByYear W28971759492021 @default.
• W2897175949 countsByYear W28971759492022 @default.
• W2897175949 countsByYear W28971759492023 @default.
• W2897175949 crossrefType "journal-article" @default.
• W2897175949 hasAuthorship W2897175949A5000111816 @default.
• W2897175949 hasAuthorship W2897175949A5000548162 @default.
• W2897175949 hasAuthorship W2897175949A5008664030 @default.
• W2897175949 hasAuthorship W2897175949A5013345797 @default.
• W2897175949 hasAuthorship W2897175949A5041250002 @default.
• W2897175949 hasAuthorship W2897175949A5043110913 @default.
• W2897175949 hasAuthorship W2897175949A5058533540 @default.
• W2897175949 hasAuthorship W2897175949A5064802725 @default.
• W2897175949 hasAuthorship W2897175949A5078315542 @default.
• W2897175949 hasBestOaLocation W28971759491 @default.
• W2897175949 hasConcept C121608353 @default.
• W2897175949 hasConcept C126322002 @default.
• W2897175949 hasConcept C170493617 @default.
• W2897175949 hasConcept C190283241 @default.
• W2897175949 hasConcept C502942594 @default.
• W2897175949 hasConcept C530470458 @default.
• W2897175949 hasConcept C54355233 @default.
• W2897175949 hasConcept C62112901 @default.
• W2897175949 hasConcept C71924100 @default.
• W2897175949 hasConcept C86803240 @default.
• W2897175949 hasConcept C95444343 @default.
• W2897175949 hasConceptScore W2897175949C121608353 @default.
• W2897175949 hasConceptScore W2897175949C126322002 @default.
• W2897175949 hasConceptScore W2897175949C170493617 @default.
• W2897175949 hasConceptScore W2897175949C190283241 @default.
• W2897175949 hasConceptScore W2897175949C502942594 @default.

• next